SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the Transplantation & Cellular Therapy Meetings of the ...
K. pneumoniae is frequently the source of hospital-acquired infections and, due to the widespread use of antibiotics in these settings, has also acquired numerous resistance genes. In fact, over ...
Advances in immunopathology have led to targeted therapies for gMG, including complement inhibitors and FcRn antagonists, offering more precise treatment options. FDA-approved drugs for gMG include ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results